The aggressive peripheral T-cell lymphomas: 2013

American Journal of Hematology

Volumn 88, Issue 10, 2013, Pages 910-918

  Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANAPLASTIC LYMPHOMA KINASE; ASPARAGINASE; BEVACIZUMAB; CLADRIBINE; CRIZOTINIB; CYCLOSPORIN; DASATINIB; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; INTERFERON REGULATORY FACTOR 4; LENALIDOMIDE; METHOTREXATE; PENTOSTATIN; PRALATREXATE; PREDNISONE; VINCRISTINE;

ACCREDITATION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; DISEASE FREE SURVIVAL; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; GENE EXPRESSION PROFILING; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MEDICAL EDUCATION; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; T CELL LYMPHOMA;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL, PERIPHERAL; PREDNISONE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; VINCRISTINE; WORLD HEALTH ORGANIZATION;

EID: 84884727679     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23536     Document Type: Article

References (82)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
2. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998;9:717-720.
3. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982;49:2112-2135.
4. Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer 1974;34(4 Suppl):1488-1503.
5. Lennert K, Stein H, Kaiserling E. Cytological and functional criteria for the classification of malignant lymphomata. Br J Cancer 1975;31 (Suppl 2):29-43.
6. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group [see comments]. Blood 1994;84:1361-1392.
7. Jaffe E, Harris N, Stein H, Vardiman J, editors. World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
8. Swerdlow SH. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: International Agency for Rsearch on Cancer; 2008.
9. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-4130.
10. Feldman AL, Law M, Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia 2009;23:574-580.
11. Siu LL, Wong KF, Chan JK, Kwong YL. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol 1999;155:1419-1425.
12. Zettl A, Ott G, Makulik A, et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol 2002;161:1635-1645.
13. Macon WR, Levy NB, Kurtin PJ, et al. Hepatosplenic alphabeta T-cell lymphomas: A report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol 2001;25:285-296.
14. Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010;115:1026-1036.
15. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007;109:4952-4963.
16. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1861.
17. Khong PL, Pang CB, Liang R, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 2008;87:613-621.
18. Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 2007;18:1685-1690.
19. Bishu S, Quigley JM, Schmitz J, et al. F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma 2007;48:1531-1538.
20. Storto G, Di Giorgio E, De Renzo A, et al. Assessment of metabolic activity by PET-CT with F-18-FDG in patients with T-cell lymphoma. Br J Haematol 2010;151:195-197.
21. Cahu X, Bodet-Milin C, Brissot E, et al. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: A study from the GOELAMS group. Ann Oncol 2011;22:705-711.
22. Casulo C, Maragulia J, Zelenetz A, et al. FDG-PET in the staging and prognosis of T-cell lymphoma [Abstract]. Ann Oncol 2011;22 (Suppl 4):Abstract #228.
23. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project [see comments]. N Engl J Med 1993;329:987-994.
24. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474-2479.
25. Savage KJ, Harris NL, Vose JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-5504.
26. Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet 1974;1:1070-1073.
27. Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008;111:4463-4470.
28. Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004;104:243-249.
29. Suzuki R, Suzumiya J, Yamaguchi M, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: Aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010;21:1032-1040.
30. Isaacson P, Wright DH. Intestinal lymphoma associated with malabsorption. Lancet 1978;1:67-70.
31. Swinson CM, Slavin G, Coles EC, Booth CC. Coeliac disease and malignancy. Lancet 1983;1:111-115.
32. Green PH, Fleischauer AT, Bhagat G, et al. Risk of malignancy in patients with celiac disease. Am J Med 2003;115:191-195.
33. Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: Clinical and histological findings from the international peripheral T-cell lymphoma project. Blood 2011;118:148-155.
34. Chott A, Haedicke W, Mosberger I, et al. Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol 1998;153:1483-1490.
35. Deleeuw RJ, Zettl A, Klinker E, et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 2007;132:1902-1911.
36. Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: A distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin [see comments]. Blood 1996;88:4265-4274.
37. Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: Case report and literature review. Clin Lymphoma Myeloma Leuk 2010;10:144-148.
38. Abramson JS, Kotton CN, Elias N, et al. Case records of the Massachusetts General Hospital. Case 8-2008. A 33-year-old man with fever, abdominal pain, and pancytopenia after renal transplantation. N Engl J Med 2008;358:1176-1187.
39. Tey SK, Marlton PV, Hawley CM, et al. Post-transplant hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen. Am J Hematol 2008;83:330-333.
40. Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116:3418-3425.
41. Brugieres L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: A report from the French Society of Pediatric Oncology. J Clin Oncol 2009;27:5056-5061.
42. Le Deley MC, Rosolen A, Williams DM, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: Results of the randomized ALCL99-vinblastine trial. J Clin Oncol 2010;28:3987-3993.
43. Advani R, Shustov AR, Brice P, et al. Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: A phase 2 study update [Abstract]. Blood 2011;117:Abstract #443.
44. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011;364:775-776.
45. Hosing C, Champlin RE. Stem-cell transplantation in T-cell non-Hodgkin's lymphomas. Ann Oncol 2011;22:1471-1477.
46. Siegert W, Agthe A, Griesser H, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med 1992;117:364-370.
47. de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol 2009;148:673-689.
48. Joly B, Frenkel V, Gaulard P, et al. Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphomas (AITL): Preliminary results in 9 patients treated in a single institution [Abstract]. Blood 2005;106:Abstrat #2686.
49. Joly B, Plonquet A, Grare M, et al. Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: Results of the phase II RAIL trial-A prospective study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) [Abstract]. J Clin Oncol 2010;28:Abstract #8049.
50. Advani R, Horwitz S, Zelenetz A, Horning SJ. Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine. Leuk Lymphoma 2007;48:521-525.
51. Bruns I, Fox F, Reinecke P, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 2005;19:1993-1995.
52. Aguiar Bujanda D. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann Oncol 2008;19:396-397.
53. Rentschler J, Herrmann R, Fischer N, et al. Response to lenalidomide in heavily pre-treated angioimmunoblastic t-cell-lymphoma (AITL) [Abstract]. Ann Oncol 2011;22 (Suppl 4):Abstract #249.
54. Marks R, Fan W, Engelhardt M, et al. Long term disease control and overall survival after early dose intensification in T-NHL depend on specific entities [Abstract]. Ann Oncol 2011;22 (Suppl 4):Abstract #101.
55. Kyriakou C, Canals C, Goldstone A, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: Complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:218-224.
56. Kyriakou C, Canals C, Finke J, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: A retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009;27:3951-3958.
57. NCCN Clinical Practice Guidelines in Oncology for Non-Hodgkins Lymphomas. (TCEL-1) 2011;Version 4.2011:www.NCCN.org.
58. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110:2316-2323.
59. Foss FM, Sjak-Shie A, Goy A, et al. Phase II study of denileukin diftitox with CHOP chemotherapy in newly diagnosed PTCL: CONCEPT trial [Abstract]. J Clin Oncol 2010;28(15 Suppl):Abstract #8045.
60. Kim SJ, Eom HS, Kim JS, et al. The efficacy of bortezomib CHOP in patients with advanced stage T or NK/T cell lymphomas: The results of multicenter phase II study [Abstract]. Blood 2010;116:Abstract #1791.
61. Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: The M. D. Anderson Cancer Center experience. Cancer 2005;103:2091-2098.
62. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998;92:76-82.
63. Corazzelli G, Frigeri F, Marcacci G, et al. Gemcitabine, ifosfamide, oxaliplatin (GIFOX) as first-line treatment in high-risk peripheral T-cell/NK lymphomas: A phase II trial [Abstract]. Blood 2010;116:Abstract #2829.
64. d'Amore F, Relander T, Lauritzsen GF, et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLs)-Overall and subtype-specific results of a phase II study from Nordic lymphoma group [Abstract]. Haematologica 2009;94 (Suppl 2):Abstract #437.
65. Relander T, Lauritzsen GF, Jantunen E, et al. Favorable outcome in ALK-negative anaplastic large-cell lymphoma following intensive induction chemotherapy and autologous stem cell transplantation (ASCT): A prospective study by the Nordic Lymphoma Group (NLG-T-01) [Abstract]. Blood 2010;116:Abstract #3566.
66. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182-1189.
67. Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011;117:5827-5834.
68. Dueck G, Chua N, Prasad A, et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010;116:4541-4548.
69. William BM, Hohenstein M, Loberiza FR, et al. Phase I/II study of dasatinib in relapsed or refractory non-Hodgin's Lymhoma (NHL) [Abstract]. Blood 2010;116:131 Abstract #288.
70. Friedberg J, Mahadevan D, Jung JA, et al. Phase 2 trial of Alisertib (MLN8237), an investigational, potent inhibitor of auror a kinase (AAK), in patients (pts) with aggressive B-an T-Cell non-Hodgkin lymphoma (NHL) [Abstract]. Blood 2011;118:46 Abstract #95.
71. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24:181-189.
72. Drenou B, Lamy T, Amiot L, et al. CD3-CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 1997;89:2966-2974.
73. Rodriguez J, Romaguera JE, Manning J, et al. Nasal-type T/NK lymphomas: A clinicopathologic study of 13 cases. Leuk Lymphoma 2000;39:139-144.
74. Nagafuji K, Fujisaki T, Arima F, Ohshima K. l-Asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 2001;74:447-450.
75. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: The NK-Cell Tumor Study Group study. J Clin Oncol 2011;29:4410-4416.
76. Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: Clinical features and treatment of 31 patients in a single center [In Process Citation]. J Clin Oncol 2000;18:795.
77. Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010;115:3664-3670.
78. Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report on a series of 21 patients. Blood 2003;102:4261-4269.
79. Jaeger G, Bauer F, Brezinschek R, et al. Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine. Ann Oncol 2008;19:1025-1026.
80. Grigg AP. 2'-Deoxycoformycin for hepatosplenic gammadelta T-cell lymphoma. Leuk Lymphoma 2001;42:797-799.
81. Machino T, Okoshi Y, Kaneko S, et al. Hepatosplenic alphabeta T-cell lymphoma successfully treated with allogeneic bone marrow transplantation. Bone Marrow Transplant 2007;39:513-514.
82. Falchook GS, Vega F, Dang NH, et al. Hepatosplenic gamma-delta T-cell lymphoma: Clinicopathological features and treatment. Ann Oncol 2009;20:1080-1085.